DOI QR코드

DOI QR Code

Overexpression of Matrix Metalloproteinase 11 in Thai Prostatic Adenocarcinoma is Associated with Poor Survival

  • Nonsrijun, Nongnuch (Department of Anatomy, Faculty of Medicine, Khon Kaen University) ;
  • Mitchai, Jumphol (Department of Pathology, Faculty of Medicine, Khon Kaen University) ;
  • Brown, Kamoltip (International College, Khon Kaen University) ;
  • Leksomboon, Ratana (College of Medicine and Public Health Ubon Ratchathani University) ;
  • Tuamsuk, Panya (Department of Anatomy, Faculty of Medicine, Khon Kaen University)
  • Published : 2013.05.30

Abstract

Background: The incidence of prostate cancer, one of the most common cancers in elderly men, is increasing annually in Thailand. Matrix metalloproteinase 11 (MMP-11) is a member of the extracellular matrix metalloproteases which has been associated with human tumor progression and clinical outcome. Aim: To quantify MMP-11 expression in prostatic adenocarcinoma tissues and to determine whether its overexpression correlates with survival outcome, and to assess its potential as a new prognostic marker. Materials and Methods: Expression of MMP-11 was analyzed using immunohistochemistry in 103 Thai patients with prostatic adenocarcinoma. Overall survival was analyzed using Kaplan-Meier methods and Cox regression models. Results: Immunoreactivity of MMP-11 was seen in the stroma of prostatic adenocarcinoma tissue samples, high expression being significantly correlated with poor differentiation in Gleason grading, pathologic tumor stage 4 (pT4), and positive-bone metastasis (p<0.05), but not age and prostatic-specific antigen (PSA) level. Patients with high levels of MMP-11 expression demonstrated significantly shorter survival (p<0.001) when compared to those with low levels. Multivariate analysis showed that MMP-11 expression and pT stage were related with survival in prostatic adenocarcinoma [hazard ratio (HR)=0.448, 95% confidence interval (95%CI)=0.212-0.946, HR=0.333, 95%CI=0.15-0.74, respectively]. Conclusions: Expression of MMP-11 is significantly associated with survival in prostatic adenocarcinoma. High levels may potentially be used for prediction of a poor prognosis.

Keywords

Matrix metalloproteinase 11;prostatic adenocarcinoma;survival time;prognostic significance

References

  1. Ahmad A, Hanby A, Dublin E, et al (1998). Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol, 152, 721-8.
  2. Alexander CM, Werb Z (1991). Extracellular matrix degradation. In 'Cell Biology of Extracellular Matrix', Ed. Hay ED. Plenum Press, New York, 255-302.
  3. Andarawewa KL, Boulay A, Masson R, et al (2003). Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res, 63, 5844-9.
  4. Arora S, Kaur J, Sharma C, et al (2005). Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation withmicrovessel density, progression, and prognosis. Clin Cancer Res, 11, 2272-84. https://doi.org/10.1158/1078-0432.CCR-04-0572
  5. Basset P, Bellocq JP, Wolf C, et al (1990). A novel Metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704. https://doi.org/10.1038/348699a0
  6. Basset P, Wolf C, Chambon P (1993). Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat, 24, 185-93. https://doi.org/10.1007/BF01833259
  7. Bergers G, Brekken R, McMahon G, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol, 2, 737-44. https://doi.org/10.1038/35036374
  8. Boulay A, Masson R, Chenard MP, et al (2001). High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res, 61, 2189-93.
  9. Chen YT, Chen WT, Huang WT, et al (2012). Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans. Kaohsiung J Med Sci, Oct; 28,545-9. https://doi.org/10.1016/j.kjms.2012.04.017
  10. Chenard MP, O'Siorain L, Shering S, et al (1996). High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer, 69, 448-51. https://doi.org/10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.0.CO;2-4
  11. Cheng CW, Yu JC, Wang HW, et al (2010). The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta, 411, 234-41. https://doi.org/10.1016/j.cca.2009.11.009
  12. Coussens LM, Tinkle CL, Hanahan D, et al (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-90. https://doi.org/10.1016/S0092-8674(00)00139-2
  13. Denys H, De Wever O, Nusgens B, et al (2004). Invasion and MMP expression profile in desmoid tumours. Br J Cancer, 90, 1443-9. https://doi.org/10.1038/sj.bjc.6601661
  14. Egeblad M, Werb Z, (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74. https://doi.org/10.1038/nrc745
  15. Escaff s, Fernandez JM, Gonzalez LO, et al (2000). Study of matrix metalloproteinases and their inhibitors in prostate cancer. Bri J Cancer, 102, 922-9.
  16. Fang J, Shing Y, Wiederschain D, et al (2000). Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA, 97, 3884-9. https://doi.org/10.1073/pnas.97.8.3884
  17. Freije JM, Baibin M, Pendas AM, et al (2003). Matrix metalloproteinases and tumor progression. Adv Exp Med Biol, 532, 91-107. https://doi.org/10.1007/978-1-4615-0081-0_9
  18. Jamnongkan W, Techasen A, Thanan R, et al (2013). Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumor Biol, 34,695-704. https://doi.org/10.1007/s13277-012-0597-7
  19. Hojilla CV, Mohammed FF, Khokha R, (2003). Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer, 89, 1817-21. https://doi.org/10.1038/sj.bjc.6601327
  20. Hourihan RN, O'Sullivan GC, Morgan JG, (2003). Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res, 23, 161-5.
  21. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. Ca Cancer J Clin, 61. 69-90.
  22. Kettunen E, Anttila S, Seppanen JK, et al (2004). Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet, 149, 98-106. https://doi.org/10.1016/S0165-4608(03)00300-5
  23. Khuhaprema T, Srivatanakul P, Attasara P, et al (2010). Cancer in Thailand Volume V 2001-2003. National Cancer Institute, 5, 7-62.
  24. Kren L, Goncharuk VN, Krenova Z, et al (2006). Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol, 42, 16-9.
  25. Madu Co, Lu Y (2010). Novel diagnostic biomarkers for prostate cancer. J Cancer, 1, 150-77.
  26. Manes S, Mira E, Barbacid MD, et al (1997). Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem, 272, 25706-12. https://doi.org/10.1074/jbc.272.41.25706
  27. Masson R, Lefebvre O, Noel A, et al (1998). In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol. 140, 1535-41 https://doi.org/10.1083/jcb.140.6.1535
  28. Mellick AS, Blackmore D, Weinstein SR, at al (2003). An assessment of MMP and TIMP gene expression in cell lines and stroma-tumour differences in microdissected breast cancer biopsies. Tumour Biol, 24, 258-70. https://doi.org/10.1159/000076140
  29. Murphy G, Segain JP, O'Shea M, et al (1993). The 28-kDa N-terminal domain of mouse stromelysin-3- has the general properties of a weak metalloproteinase. J Biol Chem, 268, 15435-41.
  30. Parks WC, Mecham RP (1998). Matrix metalloproteinases. New York: Academic Press.
  31. Pei D, Majmudar G, Weiss SJ (1994). Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem, 269, 25849-55.
  32. Pei D, Weiss SJ (1995). Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature, 375, 244-7. https://doi.org/10.1038/375244a0
  33. Soni S, Mathur M, Shukla NK, et al (2003). Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer, 107, 309-16. https://doi.org/10.1002/ijc.11366
  34. Sunil Kumar BV, Kumar KA, Padmanath K, et al (2013). Heterologous expression and functional characterization of matrix metalloproteinase-11 from canine mammary tumor. Anim Biotechnol, 24, 31-43. https://doi.org/10.1080/10495398.2012.739978
  35. Tetu B, Trudel D, Wang CS, (2006). Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer, 93, 944-8.
  36. Thorns V, Walter GF, Thorns C, ( 2003). Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res, 23, 3937-44.
  37. Tuamsuk P, Nonsrijun N, Pachirat K, et al (2011). Prostate cancer in Srinagarind Hospital. Srinagarind Med J, 26, 373-6.
  38. Wasenius VM, Hemmer S, Kettunen E, et al (2003). Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are upregulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res, 9, 68-75.
  39. Yan D, Dai H, Liu JW, (2011). Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer, 11, 151. https://doi.org/10.1186/1471-2407-11-151
  40. Zhao ZS, Chu YQ, Ye ZY, et al (2010). Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol, 41, 686-96. https://doi.org/10.1016/j.humpath.2009.10.010

Cited by

  1. Correlation between Microvascular Density and Matrix Metalloproteinase 11 Expression in Prostate Cancer Tissues: a Preliminary Study in Thailand vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6639
  2. High Expression of Matrix Metalloproteinase-11 indicates Poor Prognosis in Human Cholangiocarcinoma vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3697
  3. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients vol.76, pp.14, 2016, https://doi.org/10.1002/pros.23211